Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL

NCT06982274 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.

NCT NCT06982274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06982274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Oral Arsenic With ATRA and Minimal-Dose Chemotherapy for Newly Diagnosed Patients With Acute Promyelocytic Leukemia: a Study by the International Consortium on APL
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Phase
Phase 2
Overall status
Recruiting
Start date
October 20, 2023
Completion date
November 30, 2029
Enrollment
115 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukemia (apl)